Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.
Gaudet D, Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, Scott R, Hamilton J, Given B, Melquist S, Zhou R, Chang T, San Martin J, Watts GF, Goldberg IJ, Knowles JW, Hegele RA, Ballantyne CM. Gaudet D, et al. Among authors: chang t. NEJM Evid. 2023 Dec;2(12):EVIDoa2200325. doi: 10.1056/EVIDoa2200325. Epub 2023 Nov 17. NEJM Evid. 2023. PMID: 38320498
Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
Strnad P, Mandorfer M, Choudhury G, Griffiths W, Trautwein C, Loomba R, Schluep T, Chang T, Yi M, Given BD, Hamilton JC, San Martin J, Teckman JH. Strnad P, et al. Among authors: chang t. N Engl J Med. 2022 Aug 11;387(6):514-524. doi: 10.1056/NEJMoa2205416. Epub 2022 Jun 25. N Engl J Med. 2022. PMID: 35748699 Clinical Trial.
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.
Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, Clifton P, Hamilton J, Given B, Melquist S, Zhou R, Chang T, San Martin J, Gaudet D, Goldberg IJ, Knowles JW, Hegele RA, Ballantyne CM. Watts GF, et al. Among authors: chang t. Nat Med. 2023 Sep;29(9):2216-2223. doi: 10.1038/s41591-023-02494-2. Epub 2023 Aug 25. Nat Med. 2023. PMID: 37626170 Free PMC article. Clinical Trial.
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D. Ballantyne CM, et al. Among authors: chang t. N Engl J Med. 2024 Sep 12;391(10):899-912. doi: 10.1056/NEJMoa2404143. Epub 2024 May 28. N Engl J Med. 2024. PMID: 38804517 Clinical Trial.
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, San Martin J, Zhou R, Muhsin M, Chang T, Hellawell J, Watts GF; ARCHES-2 Trial Team. Rosenson RS, et al. Among authors: chang t. N Engl J Med. 2024 Sep 12;391(10):913-925. doi: 10.1056/NEJMoa2404147. Epub 2024 May 29. N Engl J Med. 2024. PMID: 38809174 Clinical Trial.
Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA).
Clark VC, Strange C, Strnad P, Sanchez AJ, Kwo P, Pereira VM, van Hoek B, Barjaktarevic I, Corsico AG, Pons M, Goldklang M, Gray M, Kuhn B, Vargas HE, Vierling JM, Vuppalanchi R, Brantly M, Kappe N, Chang T, Schluep T, Zhou R, Hamilton J, San Martin J, Loomba R. Clark VC, et al. Among authors: chang t. Gastroenterology. 2024 Oct;167(5):1008-1018.e5. doi: 10.1053/j.gastro.2024.06.028. Epub 2024 Jul 2. Gastroenterology. 2024. PMID: 38964420 Free article. Clinical Trial.
Global trends in surgical approach to neonatal brachial plexus palsy: a systematic review.
Levidy MF, Azer A, Shafei J, Srinivasan N, Mahajan J, Gupta S, Abdelmalek G, Pant K, Jain K, Shah Y, Zheng Z, Chuieng-Yi Lu J, Chang TN, Chu A, McGrath A. Levidy MF, et al. Among authors: chang tn. Front Surg. 2025 Jan 6;11:1359719. doi: 10.3389/fsurg.2024.1359719. eCollection 2024. Front Surg. 2025. PMID: 39840269 Free PMC article.
9,163 results